


Critical and Growing Unmet Need

- LC is a lethal complication affecting 120 K patients annually in the US

- LC diagnoses are increasing:
 - Therapeutic advances have extended patient lives, providing more time for LC to develop, increasing incidence
 - Improvements in imaging techniques increase % diagnosed



Epidemiology

- Diagnosed LC occurs in ~5% of solid tumor patients
- LC is diagnosed by satisfying two of three criteria:
 - Cerebrospinal fluid cytology positive for tumor cells (lumbar puncture / spinal tap)
 - Symptoms of cranial or nerve impairment
 - MRI of the entire CNS (preferably with gadolinium enhancement)
- However, **post-mortem, LC is present in ~20% of patients with cancer and accompanying neurological signs/symptoms**
- Breast, lung, and melanoma are most prevalent solid tumors types in patients with LC

- Sources: Globocan; American Cancer Society; UpToDate